20/20 Biolabs Q3 2026 Results: Net Loss of $1.38M, Loss Widens
For the nine months ended September 30, 2026, 20/20 Biolabs, Inc. reported a net loss of $5.06 million on revenues of $1.46 million, compared to a net loss of $2.43 million on revenues of $1.51 million in the prior year period. The company experienced a significant increase in operating expenses, primarily driven by sales, general, and administrative costs, and underwent a major capital restructuring involving the conversion of multiple preferred stock series into common stock.
- Key figure
- Net loss $1.38M